Cardiorenal Syndrome: Patofisiologi, Diagnosis, dan Tatalaksana
DOI:
https://doi.org/10.55175/cdk.v48i6.81Kata Kunci:
sindrom kardiorenal, ginjal, gagal jantung, CederaAbstrak
Sindrom kardiorenal merupakan gangguan yang melibatkan jantung dan ginjal; disfungsi akut atau kronik satu organ dapat menginduksi disfungsi akut atau kronik organ lain. Disfungsi ginjal terkait gagal jantung akut, dan sebaliknya, menyebabkan morbiditas dan mortalitas yang cukup tinggi. Tinjauan ini membantu menjelaskan hubungan antara cedera ginjal dan gagal jantung dan faktor-faktor yang berperan penting dalam kedua patologi ini. Identifikasi dini memungkinkan perawatan yang lebih efektif dan rawat inap yang lebih singkat. Pendekatan multidisiplin yang melibatkan ahli jantung dan ginjal sangat penting.
Cardiorenal syndrome is a disorder involving both the heart and kidneys; acute orchronic dysfunction in one organ may induce acute or chronic dysfunctionin the other organ. Renal dysfunction associated with acute heart failure, and vice versa, causes fairly high morbidity and mortality. This review explains the relationship between kidney injury and heart failure and factors that play an important role in both pathologies. Early identification will allow more effective treatment and shorter hospitalizations. A multidisciplinary approach involving cardiologists and nephrologists is imperative.
Unduhan
Referensi
Shah B, Greaves K. The cardiorenal syndrome: A review. Internat J Nephrol. 2010;2011:1-11.
Raina R, Nair N, Chakraborty R, Nemer L, Dasgupta R, Varian K. An update on the pathophysiology and treatment of cardiorenal syndrome. Cardiology Res. 2020;11(2):76.
Ronco C, Di Lullo L. Cardiorenal syndrome in Western countries: Epidemiology, diagnosis and management approaches. Kidney Dis. 2016;2(4):151-63.
Ronco C, Bellasi A, Di Lullo L. Cardiorenal syndrome: An overview. Adv Chronic Kidney Dis. 2018;25(5):382-90.
Takahama H, Kitakaze M. Pathophysiology of cardiorenal syndrome in patients with heart failure: Potential therapeutic targets. Am J Physiol Heart Circ Physiol. 2017;313(4):715-21.
Annual data report: Morbidity and mortality in patients with CKD [Internet]. 2018. Available from: https://adr.usrds.org/2020/chronic-kidney-disease/3-mobidityand-mortality-in-patients-with-ckd.
Rampengan SH. Cardiorenal syndrome type 1: A literature review. Bali Med J. 2019;8:1549.
Uduman J. Epidemiology of cardiorenal syndrome. Adv Chronic Kidney Dis. 2018;25(5):391-9.
Di Lullo L, House A, Gorini A, Santoboni A, Russo D, Ronco C. Chronic kidney disease and cardiovascular complications. Heart Fail Rev. 2015;20(3):259-72.
Di Lullo L, Bellasi A, Cozzolino M. Pathophysiology of the cardiorenal syndromes types 1–5: Updates from the Eleventh Consensus Conference of the Acute Dialysis Quality Initiative (ADQI). Cardio-Nephrology: Springer; 2017. p. 131-43.
Rangaswami J, Bhalla V, Blair JE, Chang TI, Costa S, Lentine KL, et al. Cardiorenal syndrome: Classification, pathophysiology, diagnosis, and treatment strategies: A scientific statement from the American Heart Association. Circulation. 2019;139(16):840-78.
Beigel R, Cercek B, Siegel RJ, Hamilton MA. Echo-Doppler hemodynamics: An important management tool for today’s heart failure care. Circulation. 2015;131(11):1031-4.
Costanzo MR. Ultrafiltration in acute heart failure. Cardiac Failure Review. 2019;5(1):9.
Vinod P, Krishnappa V, Chauvin AM, Khare A, Raina R. Cardiorenal syndrome: Role of arginine vasopressin and vaptans in heart failure. Cardiol Res. 2017;8(3):87.
Solomon SD, Claggett B, McMurray JJ, Hernandez AF, Fonarow GC. Combined neprilysin and renin–angiotensin system inhibition in heart failure with reduced ejection fraction: A meta‐analysis. Eur J Heart Failure. 2016;18(10):1238-43.
Damman K, Gori M, Claggett B, Jhund PS, Senni M, Lefkowitz MP, et al. Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. JACC: Heart Failure. 2018;6(6):489-98.
Vardeny O, Wu DH, Desai A, Rossignol P, Zannad F, Pitt B, et al. Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: Insights from RALES (Randomized Aldactone Evaluation Study). J Am Coll Cardiol. 2012;60(20):2082-9.
Ferreira JP, Rossello X, Pitt B, Rossignol P, Zannad F. Eplerenone in patients with myocardial infarction and “mid-range” ejection fraction: An analysis from the EPHESUS trial. Clin Cardiol. 2019;42(11):1106-12.
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey Jr DE, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):1810-52.
Unduhan
Diterbitkan
Cara Mengutip
Terbitan
Bagian
Lisensi
Hak Cipta (c) 2021 Cermin Dunia Kedokteran
Artikel ini berlisensi Creative Commons Attribution-NonCommercial 4.0 International License.
